Investor sentiment shift after earnings-focused rating upgrade
Adaptive Biotechnologies (ADPT) is back on investors’ radar after a recent upgrade to a Zacks Rank #2 (Buy). The move is tied to higher earnings estimates and a more constructive view on its earnings outlook.
See our latest analysis for Adaptive Biotechnologies.
The recent Zacks upgrade comes as Adaptive Biotechnologies’ share price has rallied, with a 28.81% 1 month share price return and 59.01% 3 month share price return. Its 1 year total shareholder return of 114.43% contrasts with a 5 year total shareholder return that remains down 36.25%, suggesting improving momentum from a weaker longer term base.
If you are looking for more ways to position around health focused data and AI themes, it may be worth scanning for other opportunities using our 39 healthcare AI stocks
The sharp re-rating in Adaptive Biotechnologies after the Zacks upgrade could signal growing conviction in its immune medicine platform, or it could be sentiment running ahead of fundamentals. How does today’s valuation stack up against the business reality?
Most Popular Narrative: 12.1% Overvalued
Adaptive Biotechnologies last closed at $22.58, while the most widely followed narrative pegs fair value at $20.14, so current pricing sits above that anchor.
Marked improvement in profitability, with the MRD segment now EBITDA positive and company-wide cash burn improving 36% year-over-year, signals the business reaching scale and positions Adaptive for operating leverage and expanding net margins as revenue continues to rise.
Curious what earnings profile and margin path are embedded in that $20.14 figure, and how revenue growth assumptions tie into a rich future multiple? The full narrative lays out the numbers that make this valuation tick.
Result: Fair Value of $20.14 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, investors still need to weigh the risk that ongoing losses and cash burn, along with reliance on major partnerships, could weaken confidence in the current Adaptive Biotechnologies narrative.
Find out about the key risks to this Adaptive Biotechnologies narrative.
Another View: SWS DCF Model Points To Upside
While the analyst narrative pegs Adaptive Biotechnologies as 12.1% overvalued at $22.58 against a $20.14 fair value, the Simply Wall St DCF model presents a different perspective, with an intrinsic value of $28.68. If cash flows track those inputs, today’s price could appear conservative.
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Adaptive Biotechnologies for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 50 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
With sentiment clearly split on Adaptive Biotechnologies, it makes sense to review the numbers yourself and decide quickly where you stand. To weigh the concerns alongside the potential upsides in one place, start with our breakdown of 3 key rewards and 1 important warning sign
Looking for more investment ideas beyond Adaptive Biotechnologies?
If Adaptive Biotechnologies has caught your attention, do not stop there. Use the Simply Wall St Screener today so you do not miss other potential opportunities.
- Spot potential mispricing by scanning 50 high quality undervalued stocks that combine quality fundamentals with specific valuation metrics.
- Review solid balance sheet and fundamentals stocks screener (48 results) to focus on companies with stronger financial positions.
- Explore screener containing 20 high quality undiscovered gems to identify companies that may be less widely followed.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com